Oncology Drug Development and Approval of Systemic Anticancer Therapy by the U.S. Food and Drug Administration

Por Martell, Robert E., Sermer, David, Getz, Kenneth, Kaitin, Kenneth I.
Publicado em 2013

Metformin, diabetes, and survival among US veterans with colorectal cancer

Por Paulus, Jessica K., Williams, Christina D., Cossor, Furha I., Kelley, Michael J., Martell, Robert E.
Publicado no Cancer Epidemiol Biomarkers Prev (2016)

Metformin, Diabetes, and Survival among U.S. Veterans with Colorectal Cancer – Response to Letter

Por Paulus, Jessica K., Williams, Christina D., Cossor, Furha I., Kelley, Michael J., Martell, Robert E.
Publicado no Cancer Epidemiol Biomarkers Prev (2017)

Prospective Evaluation of Effect of Metformin on Activation of AMP-activated Protein Kinase (AMPK) and Disease Control in a Sub-group Analysis of Patients with GI Malignancies

Por Godara, Amandeep, Siddiqui, Nauman S., Hachem, Hilal, Tsichlis, Philip N., Martell, Robert E., Saif, Muhammad Wasif
Publicado no J Cell Signal (2020)

The class-I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6-independent mechanism

Por Buglio, Daniela, Mamidipudi, Vidya, Khaskhely, Noor M., Brady, Helen, Heise, Carla, Besterman, Jeffrey, Martell, Robert E., MacBeth, Kyle, Younes, Anas
Publicado em 2010

EVALUATION OF THE PHARMACODYNAMIC EFFECTS OF MGCD0103 FROM PRECLINICAL MODELS TO HUMAN, USING A NOVEL HDAC ENZYME ASSAY

Por Bonfils, Claire, Kalita, Ann, Dubay, Marja, Siu, Lillian L., Carducci, Michael A., Reid, Gregory, Martell, Robert E., Besterman, Jeffrey M., Li, Zuomei
Publicado em 2008

Diabetes, Metformin Use, and Colorectal Cancer Survival in Postmenopausal Women

Por Cossor, Furha Iram, Adams-Campbell, Lucile L., Chlebowski, Rowan T., Gunter, Marc J, Johnson, Karen, Martell, Robert E., McTiernan, Anne, Simon, Michael S., Rohan, Thomas, Wallace, Robert B., Paulus, Jessica K.
Publicado em 2013

Phase II Study of the Histone Deacetylase Inhibitor MGCD0103 in Patients with Previously Treated Chronic Lymphocytic Leukemia

Por Blum, Kristie A., Advani, Anjani, Fernandez, Louis, Van Der Jagt, Richard, Brandwein, Joseph, Kambhampati, Suman, Kassis, Jeannine, Davis, Melanie, Bonfils, Claire, Dubay, Marja, Dumouchel, Julie, Drouin, Michel, Lucas, David M., Martell, Robert E., Byrd, John C.
Publicado em 2009

Phase II Study of Mocetinostat (MGCD0103) In Patients with Relapsed and Refractory Classical Hodgkin Lymphoma

Por Younes, Anas, Oki, Yasuhiro, Bociek, R. Gregory, Kuruvilla, John, Fanale, Michelle, Neelapu, Sattva, Copeland, Amanda, Buglio, Daniela, Galal, Ahmed, Besterman, Jeffrey, Li, Zuomei, Drouin, Michel, Patterson, Tracy, Ward, M. Renee, Paulus, Jessica K., Ji, Yuan, Medeiros, L. Jeffrey, Martell, Robert E.
Publicado no Lancet Oncol (2011)

Phase I Study of MGCD0103 Given As a Three-Times-Per-Week Oral Dose in Patients With Advanced Solid Tumors

Por Siu, Lillian L., Pili, Roberto, Duran, Ignacio, Messersmith, Wells A., Chen, Eric X., Sullivan, Rana, MacLean, Martha, King, Serina, Brown, Shirley, Reid, Gregory K., Li, Zuomei, Kalita, Ann M., Laille, Eric J., Besterman, Jeffrey M., Martell, Robert E., Carducci, Michael A.
Publicado em 2008

Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia

Por Garcia-Manero, Guillermo, Assouline, Sarit, Cortes, Jorge, Estrov, Zeev, Kantarjian, Hagop, Yang, Hui, Newsome, Willie M., Miller, Wilson H., Rousseau, Caroline, Kalita, Ann, Bonfils, Claire, Dubay, Marja, Patterson, Tracy-Ann, Li, Zuomei, Besterman, Jeffrey M., Reid, Gregory, Laille, Eric, Martell, Robert E., Minden, Mark
Publicado em 2008